Devita, Hellman, and Rosenberg's Cancer

LWBK1006-33 LWW-Govindan-Review November 24, 2011 11:25

CHAPTER 33 MYELODYSPLASTIC

SYNDROMES

SAIAMA N. WAQAR

DIRECTIONS Each of the numbered items below is followed by lettered answers. Select the

ONE lettered answer that is BEST in each case unless instructed otherwise.

QUESTIONS

Question 33.1. Which of the following cytogenetic abnormalities in a patient with

myelodysplastic syndromes (MDS) are indicative of a favorable prog-

nosis?

A. del(5q)

B. del (20q)

C. –Y

D. All of the above

Question 33.2. Which of the following is NOT a prognostic variable in the International

Prognostic Scoring System (IPSS) for MDS?

A. Karyotype

B. Age

C. Percentage of blasts in the bone marrow

D. Number of cytopenias

Question 33.3. A 55-year-old postmenopausal woman presents with anemia. Her

hemoglobin is 10 g/dL, mean corpuscular volume is 105 fL, white blood

cell count is 7,000/L, and platelet count is 450,000/L. Her ferritin is

400 g/L and erythropoietin level is 600U/L. Her serum creatinine, liver

enzymes, iron studies, B12, and folate levels are normal. Bone marrow

biopsy shows dyserythropoiesis and hypolobulated megakaryocytes, with

2% blasts. Cytogenetics reveal del (5q). Which of the following is the most

appropriate therapy?

A. Azacitidine

B. Decitabine

C. Lenalidomide

D. Vorinostat

Corresponding Chapter inCancer: Principles & Practice of Oncology,Ninth Edition: 135 (Myelodysplastic Syn-

dromes).

459